Jul 25, 2023, 14:59 by ASAM Weekly Editors

Remove Arbitrary Barrier to Evidence-based Treatment for Stimulant Use Disorder

Jul 24, 2023, 11:55 by Richard Rawson, PhD for the Motivational Incentives Policy Group

Although the current overdose crisis in the US is almost universally referred to as the “opioid” or “fentanyl crisis”1,2, the overdose death rate associated with psychomotor stimulants including methamphetamine and cocaine has also dramatically increased in recent years.

Jul 20, 2023, 14:37 by Molly McGrath

For the second year in a row, ASAM has assembled a mid-year report to ensure that members are up to date on what took place in their states and nationwide.

Jul 20, 2023, 09:37 by ASAM Weekly Editors

Questioning the Right to Pain Relief and Its Role in the Opioid Epidemic

Jul 19, 2023, 18:47 by Molly McGrath

Today, the American Society of Addiction Medicine (ASAM) applauded the House Energy & Commerce Committee for voting to include key provisions in the bipartisan H.R. 4531 – the SUPPORT for Patients and Communities Reauthorization Act, legislation which aims to address the nation’s ongoing addiction and overdose crisis.

Jul 13, 2023, 10:16 by Molly McGrath

Today, July 13th, the House Energy and Commerce Subcommittee on Health will hold a markup of 17 bills, including HR 4531 - the Support for Patients and Communities Reauthorization Act.

Jul 12, 2023, 13:44 by ASAM Weekly Editors

Xylazine effects on opioid-induced brain hypoxia

Jul 6, 2023, 18:58 by Molly McGrath

Jul 4, 2023, 13:54 by ASAM Weekly Editors

Psychedelics reopen the social reward learning critical period

Jun 28, 2023, 17:54 by Molly McGrath

Jun 28, 2023, 12:42 by ASAM Weekly Editors

Reduced Stress-Related Neural Network Activity Mediates the Effect of Alcohol on Cardiovascular Risk

Jun 27, 2023, 09:19 by Bob Davis

The Drug Enforcement Administration is warning the public of a widespread fraud scheme in which scammers impersonate DEA agents in an attempt to extort money or steal personal identifiable information.

Jun 21, 2023, 10:58 by ASAM Weekly Editors

Signaling-specific inhibition of the CB1 receptor for cannabis use disorder

Jun 20, 2023, 10:05 by Molly McGrath

This week, the House Energy and Commerce Subcommittee on Health will take steps to advance a range of legislation that aims to strengthen the nation’s approach to the addiction and overdose crisis—and, ultimately, save lives. However, we are deeply disappointed that the Subcommittee has chosen to leave the Modernizing Opioid Treatment Access Act (MOTAA) (H.R. 1359) off its docket for this week’s legislative hearing. MOTAA is a bipartisan bill that would create a small, but necessary, adjustment in a longstanding closed system of clinics. It would accomplish this by empowering expert addiction specialist physicians — not just clinicians working in an opioid treatment program (OTP) — to prescribe methadone to treat opioid use disorder (OUD). The bill has received broad support from national organizations, including the American Medical Association and the American Pharmacists Association.

Jun 16, 2023, 18:19 by Molly McGrath

Jun 14, 2023, 12:11 by ASAM Weekly Editors

The Future of Psychedelic Therapy and Addiction Treatment

Jun 12, 2023, 09:49 by David E. Smith, MD, DFASAM

With the resurgence of scientific interest into the healing properties of psychedelics, current studies are investigating potential therapeutic breakthroughs in the treatment of substance use and mental health disorders. The landscape of addiction treatment faces new challenges, as evidenced during the Covid pandemic. With dual-diagnoses on the rise, promising new treatment modalities are needed more than ever.

Jun 7, 2023, 10:00 by ASAM Weekly Editors

Increasing overdose deaths among Black Americans

Jun 5, 2023, 12:53 by Molly McGrath

Under the MOTAA, non-OTP clinicians and pharmacies would remain subject to a variety of federal (and state) laws and regulations that guard against diversion of controlled medications. Expert clinical discretion would determine the frequency of counseling and drug testing in patient care, subject to any applicable state regulations. M-OTAA would not change the longstanding federal requirement that all controlled medication prescriptions by authorized prescribers must be issued for a legitimate medical purpose in the usual course of professional practice.

Jun 2, 2023, 10:49 by Bob Davis

This comprehensive on-demand course is designed to equip healthcare professionals with the latest scientific knowledge and best practices concerning the prescription of opioids for pain management.